These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 30796023)

  • 21. Preface.
    Michaelis LC
    Best Pract Res Clin Haematol; 2019 Mar; 32(1):1-2. PubMed ID: 30927968
    [No Abstract]   [Full Text] [Related]  

  • 22. Jak2V617F driven myeloproliferative neoplasm occurs independently of interleukin-3 receptor beta common signaling.
    Vu T; Austin R; Kuhn CP; Bruedigam C; Song A; Guignes S; Jacquelin S; Ramshaw HS; Hill GR; Lopez AF; Lane SW
    Haematologica; 2016 Mar; 101(3):e77-80. PubMed ID: 26589916
    [No Abstract]   [Full Text] [Related]  

  • 23. Programmed Cell Death Receptor (PD-1) Ligand (PD-L1) expression in Philadelphia chromosome-negative myeloproliferative neoplasms.
    Wang JC; Chen C; Kundra A; Kodali S; Pandey A; Wong C; Cheung T; Gotlieb V; Joseph G; Tribie S
    Leuk Res; 2019 Apr; 79():52-59. PubMed ID: 30851544
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Non-internal tandem duplication (ITD), non-tyrosine kinase domain (TKD) FLT3 mutations in myeloid malignancies: A brief report of 10 patients.
    Higgins A; Mangaonkar AA; Hefazi M; Viswanatha D; Horna P; Foran J; Gangat N
    Leuk Res; 2018 Sep; 72():1-4. PubMed ID: 30055376
    [No Abstract]   [Full Text] [Related]  

  • 25. Defining the Boundary Between Myelodysplastic Syndromes and Myeloproliferative Neoplasms.
    Loghavi S; Wang SA
    Surg Pathol Clin; 2019 Sep; 12(3):651-669. PubMed ID: 31352979
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Successful Imatinib therapy as a bridge to transplant in an atypical myeloproliferative neoplasm.
    Hueso T; Johnson-Ansah H; Decamp M; Maitre E; Henry A; Mensi S; Vilque JP; Chantepie S; Damaj G
    Curr Res Transl Med; 2019 Nov; 67(4):149-151. PubMed ID: 31153956
    [No Abstract]   [Full Text] [Related]  

  • 27. Vorinostat synergizes with antioxidant therapy to target myeloproliferative neoplasms.
    Cardoso BA; Ramos TL; Belo H; Vilas-Boas F; Real C; Almeida AM
    Exp Hematol; 2019 Apr; 72():60-71.e11. PubMed ID: 30769020
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Combination therapy with ruxolitinib plus 5-azacytidine or continuous infusion of low dose cytarabine is feasible in patients with blast-phase myeloproliferative neoplasms.
    Mwirigi A; Galli S; Keohane C; Raj K; Radia DH; Harrison CN; McLornan DP
    Br J Haematol; 2014 Dec; 167(5):714-6. PubMed ID: 25048366
    [No Abstract]   [Full Text] [Related]  

  • 29. Heterogeneity in myeloproliferative neoplasms: Causes and consequences.
    O'Sullivan J; Mead AJ
    Adv Biol Regul; 2019 Jan; 71():55-68. PubMed ID: 30528537
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Second malignancies in patients with myeloproliferative neoplasms: a population-based cohort study of 9379 patients.
    Landtblom AR; Bower H; Andersson TM; Dickman PW; Samuelsson J; Björkholm M; Kristinsson SY; Hultcrantz M
    Leukemia; 2018 Oct; 32(10):2203-2210. PubMed ID: 29535425
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A comparison of qPCR and ddPCR used for quantification of the JAK2 V617F allele burden in Ph negative MPNs.
    Link-Lenczowska D; Pallisgaard N; Cordua S; Zawada M; Czekalska S; Krochmalczyk D; Kanduła Z; Sacha T
    Ann Hematol; 2018 Dec; 97(12):2299-2308. PubMed ID: 30056580
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Targeting Splicing in the Treatment of Myelodysplastic Syndromes and Other Myeloid Neoplasms.
    Brierley CK; Steensma DP
    Curr Hematol Malig Rep; 2016 Dec; 11(6):408-415. PubMed ID: 27492253
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinicopathologic and molecular characterization of myeloid neoplasms harboring isochromosome 17(q10).
    Visconte V; Tabarroki A; Zhang L; Hasrouni E; Gerace C; Frum R; Ai J; Advani AS; Duong HK; Kalaycio M; Saunthararajah Y; Sekeres MA; His ED; Shetty S; Rogers HJ; Tiu RV
    Am J Hematol; 2014 Aug; 89(8):862. PubMed ID: 24796269
    [No Abstract]   [Full Text] [Related]  

  • 34. 7q22 deletion in myeloid malignancies: be attentive to the design of the FISH probe.
    Struski S; Luquet I
    Ann Biol Clin (Paris); 2019 Apr; 77(2):229-230. PubMed ID: 30907375
    [No Abstract]   [Full Text] [Related]  

  • 35. Treatment of the myeloid/lymphoid neoplasm with FGFR1 rearrangement with FGFR1 inhibitor.
    Verstovsek S; Subbiah V; Masarova L; Yin CC; Tang G; Manshouri T; Asatiani E; Daver NG
    Ann Oncol; 2018 Aug; 29(8):1880-1882. PubMed ID: 29767670
    [No Abstract]   [Full Text] [Related]  

  • 36. Contemporary Use of Interferon Therapy in the Myeloproliferative Neoplasms.
    Foucar CE; Stein BL
    Curr Hematol Malig Rep; 2017 Oct; 12(5):406-414. PubMed ID: 28948521
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Sequential B-lymphoid and myeloid blastic transformation of Philadelphia chromosome-negative myeloproliferative neoplasm.
    Hu AY; Zhou T
    Br J Haematol; 2019 Jan; 184(1):8. PubMed ID: 30407632
    [No Abstract]   [Full Text] [Related]  

  • 38. TP53 and therapy-related myeloid neoplasms.
    Chung J; Sallman DA; Padron E
    Best Pract Res Clin Haematol; 2019 Mar; 32(1):98-103. PubMed ID: 30927980
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pathogenesis of myeloproliferative neoplasms.
    Skoda RC; Duek A; Grisouard J
    Exp Hematol; 2015 Aug; 43(8):599-608. PubMed ID: 26209551
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A prospective evaluation of vitamin B1 (thiamine) level in myeloproliferative neoplasms: clinical correlations and impact of JAK2 inhibitor therapy.
    Gangat N; Phelps A; Lasho TL; Finke CM; Vallapureddy R; Hanson CA; Ketterling RP; Patnaik MM; Pardanani A; Tefferi A
    Blood Cancer J; 2019 Jan; 9(2):11. PubMed ID: 30679417
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.